What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?

[1]  J. Byun,et al.  Correction to: Inter-reader reliability of CT Liver Imaging Reporting and Data System according to imaging analysis methodology: a systematic review and meta-analysis , 2021, European Radiology.

[2]  J. Byun,et al.  Inter-reader reliability of CT Liver Imaging Reporting and Data System according to imaging analysis methodology: a systematic review and meta-analysis , 2021, European Radiology.

[3]  Kathryn J Fowler,et al.  Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10–19 mm) HCC on extracellular contrast-enhanced MRI , 2020, Abdominal Radiology.

[4]  E. Hecht,et al.  Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma. , 2020, AJR. American journal of roentgenology.

[5]  J. Han,et al.  Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid–enhanced liver MRI , 2020, European Radiology.

[6]  Y. Chung,et al.  CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. , 2020, Journal of the American College of Radiology : JACR.

[7]  R. Santambrogio,et al.  LI-RADS to categorize liver nodules in patients at risk of HCC: tool or a gadget in daily practice? , 2020, La radiologia medica.

[8]  C. Sirlin,et al.  Editorial for "Interreader Agreement of Liver Imaging Reporting and Data System on MRI: A Systematic Review and Meta Analysis". , 2020, Journal of magnetic resonance imaging : JMRI.

[9]  Young Kon Kim,et al.  Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS , 2020, European Radiology.

[10]  S. Park,et al.  Interreader Agreement of Liver Imaging Reporting and Data System on MRI: A Systematic Review and Meta-Analysis. , 2020, Journal of magnetic resonance imaging : JMRI.

[11]  Young Kon Kim,et al.  Magnetic Resonance Imaging With Extracellular Contrast Detects Hepatocellular Carcinoma With Greater Accuracy Than With Gadoxetic Acid or Computed Tomography. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  Kathryn J Fowler,et al.  Liver Imaging Reporting and Data System Version 2018: Impact on Categorization and Hepatocellular Carcinoma Staging , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[13]  P. Kim,et al.  Arterial Subtraction Images of Gadoxetate-Enhanced MRI Improve Diagnosis of Early-Stage Hepatocellular Carcinoma. , 2019, Journal of hepatology.

[14]  P. Zhao,et al.  Diagnostic performance of MR for hepatocellular carcinoma based on LI‐RADS v2018, compared with v2017 , 2019, Journal of magnetic resonance imaging : JMRI.

[15]  Sang Min Lee,et al.  LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI. , 2019, Radiology.

[16]  Kathryn J Fowler,et al.  Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review. , 2019, Gastroenterology.

[17]  Tyler J. Fraum,et al.  Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018 , 2019, Abdominal Radiology.

[18]  Prashanth Rawla,et al.  Update in global trends and aetiology of hepatocellular carcinoma , 2018, Contemporary oncology.

[19]  Kathryn J Fowler,et al.  Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. , 2018, Radiology.

[20]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[21]  B. Song,et al.  Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis , 2018, World journal of gastroenterology.

[22]  E. Abdelbary,et al.  Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study , 2018, European Radiology.

[23]  C. Sirlin,et al.  Effect of threshold growth as a major feature on LI-RADS categorization , 2017, Abdominal Radiology.

[24]  S. Behr,et al.  Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas , 2016, Abdominal Radiology.

[25]  C. Sirlin,et al.  Update on the Liver Imaging Reporting and Data System: What the Pathologist Needs to Know , 2015, Advances in anatomic pathology.

[26]  Kathryn J Fowler,et al.  LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound , 2017, Abdominal Radiology.

[27]  Kathryn J Fowler,et al.  LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents , 2017, Abdominal Radiology.

[28]  C. Sirlin,et al.  LI-RADS® algorithm: CT and MRI , 2017, Abdominal Radiology.